Bioanalysis of Small Molecules & Generics
Bioanalysis of Small Molecules & Generics
KYMOS specialises in world-class bioanalysis of small molecules from fast in vivo and in vitro ADMET screenings to preclinical toxicokinetic, bioavailability and pharmacokinetic studies, drug-drug interaction studies as well as clinical trials including first in man and dose escalation studies. We are a GLP-certified and GCP compliant multinational CRO with broad experience working with large generic companies in need of full bioequivalence studies, and small biotech innovators carrying out basic R&D. We also work with animal health firms to carry out residue depletion studies. Our experienced team can support you in these specialist areas:
• Preclinical studies
• PK (pharmacokinetics) and PD (pharmacodynamic) calculations and statistics
• Metabolite identification and quantitation
• Toxicokinetics
• Biomarkers/Pharmacodynamics
• Clinical studies
• Phase I-IV pharmacokinetics including first-in-man dose escalation studies
• Drug-drug interaction studies
• Biomarkers/Pharmacodynamics
• Bioequivalence studies
• Percutaneous absorption
• Residue depletion studies
• Absorption studies
PRECLINICAL, CLINICAL AND BIOEQUIVALENCE STUDIES
Our bioanalysis experts are experienced in the comprehensive management of preclinical and clinical bioanalytical studies from phases I to IV as well as bioequivalences; offering end-to-end service from IMPD review to final reporting. We work in alliance with reputed European preclinical and clinical centers following EMA/FDA guidelines and operating with most animal models including rats, mice, rabbits, minipigs, cats, dogs, non-human primates, swine, cattle, sheep, poultry and horses. High-quality standards, narrow timelines and competitive prices are key elements for our delivery.
